Seeking Alpha
 

Novartis AG (NVS)

- NYSE
  • Tue, Jul. 21, 7:37 AM
    • Novartis (NYSE:NVS) Q2 results ($M): Total Revenues: 12,694 (-5.3%); Pharmaceuticals: 7,847 (-4.3%); Alcon: 2,559 (-9.2%); Sandoz: 2,288 (-1.8%).
    • Net Income: 1,838 (-28.9%); EPS: 0.75 (-27.2%); CF Ops: 2,910 (-12.9%); Gross Profit: 8,409 (-12.1%).
    • Key Product Sales: Gleevec/Glivec: 1,184 (-1.3%); Gilenya: 700 (+15.5%); Lucentis: 537 (-13.2%); Afinitor/Votubia: 423 (+10.2%); Sandostatin: 413 (-1.0%); Diovan/Co-Diovan: 333 (-55.2%); Tasigna: 412 (+10.5%); Galvus: 273; Exforge: 272 (-26.5%).
    • 2015 Guidance: Group Net Sales Growth: mid single digit (unch); Core Group Operating Income Growth: high single digit (unch); Pharmaceuticals Sales Growth: mid single digit (unch); Alcon Sales Growth: low single digit from mid-to-high single digit; Sandoz Sales Growth: high single digit from mid single digit.
    | Comment!
  • Tue, Jul. 21, 6:16 AM
    • Novartis (NYSE:NVS): Q2 EPS of $1.27 beats by $0.03.
    • Revenue of $12.69B (-4.9% Y/Y) beats by $240M.
    • Press Release
    | Comment!
  • Tue, Jul. 21, 3:45 AM
    • Novartis' (NYSE:NVS) second-quarter profit fell 32% from the same period last year, as the drug giant got hit by a strong dollar and weak results from its eye-care treatment business.
    • Net income fell to $1.86B, or $0.77 per share in the quarter ended in June vs. $2.72B a year earlier. Core net income fell 8%.
    • Novartis also confirmed its full year outlook, with net sales expected to grow in the mid-single digits and core operating income to grow at a faster, high-single-digit rate.
    | Comment!
  • Mon, Jul. 20, 5:30 PM
  • Thu, Apr. 23, 7:37 AM
    • Novartis (NYSE:NVS) Q1 results ($M): Total Revenues: 11,935 (-14.9%); Pharmaceuticals: 7,140 (-5.6%); Alcon: 2,558 (-3.2%); Sandoz: 2,237 (-3.5%).
    • Net Income: 13,005 (+338.2%); EPS: 5.32 (+347.1%); CF Ops: 1,704 (+27.1%); Quick Assets: 7,363 (-4.6%); Operating Earnings: 2,785 (-20.2%).
    • Key Product Sales: Gleevec/Glivec: 1,070 (-2.5%); Gilenya: 638 (+15.6%); Lucentis: 539 (-13.1%); Afinitor/Votubia: 388 (+8.7%); Sandostatin: 385 (+0.3%); Diovan/Co-Diovan: 372 (-53.7%); Tasigna: 372 (+10.4%).
    • 2015 Guidance: Group Net Sales Growth: Mid-single digit (unch).
    | Comment!
  • Thu, Apr. 23, 5:26 AM
    • Novartis (NYSE:NVS): Q1 EPS of $1.33 beats by $0.14.
    • Revenue of $11.94B misses by $960M.
    • Shares +1.3% PM.
    • Press Release
    | 1 Comment
  • Tue, Jan. 27, 7:13 AM
    • Novartis (NYSE:NVS) Q4 results ($M): Revenues: 14,633 (-3.0%); Pharmaceuticals: 7,860 (-5.6%); Alcon: 2,703 (+1.8%); Sandoz: 2,512 (+4.2%); Vaccines: 494 (-24.6%); Consumer Health: 1,064 (+2.9%).
    • COGS: 5,369 (+1.1%); R&D Expense: 2,753 (+2.1%); SG&A Expense: 3,676 (-23.0%); Net Income: 1,487 (-27.7%); EPS: 0.62 (-24.4%); CF Ops: 5,205 (+17.0%); Quick Assets: 13,862 (+50.3%).
    • Gross Profit: 9,504 (-5.4%); COGS: 36.7% (+4.1%); Gross Margin: 64.9% (-0.2%); Operating Profit: 1,172 (-50.6%); Operating Earnings Yield: 8.0% (-49.1%); Net Earnings Yield: 10.2% (-25.5%).
    • Key Product Sales: Gleevec/Glivec: 1,237 (+0.8%), Gilenya: 666 (+26.4%), Lucentis: 588 (-6.7%), Tasigna: 428 (+21.6%), Afinitor/Votubia: 426 (+18.0%), Sandostatin: 416 (0.0%).
    • 2015 Guidance: Group Net Sales Growth: Mid-single digit; Core Group Operating Income Growth: High-single digit; Pharmaceuticals Growth: Mid-single digit; Alcon Growth: Mid-to-high single digit; Sandoz Growth: Mid-single digit.
    | Comment!
  • Tue, Jan. 27, 6:09 AM
    • Novartis (NYSE:NVS): Q4 EPS of $1.21 in-line.
    • Revenue of $14.63B (-2.0% Y/Y) beats by $50M.
    • Shares +1.7% PM.
    • Press Release
    | Comment!
  • Mon, Jan. 26, 5:30 PM
  • Oct. 28, 2014, 7:22 AM
    • Novartis (NYSE:NVS) Q3 results ($M): Total Revenue: 14,704 (+2.6%); Pharmaceuticals: 7,925 (+0.4%); Alcon: 2,665 (+5.0%); Sandoz: 2,401 (5.6%); Vaccines: 588 (-1.0%); Consumer Health: 1,125 (+8.3%).
    • COGS: 5,096 (+3.8%); R&D Expense: 2,372 (-1.9%); SG&A Expense: 4,227 (+0.0%); Net Income: 3,240 (+43.1%); EPS: 1.37 (+52.2%); CF Ops: 4,011 (-8.4%); Quick Assets: 10,427 (+42.1%).
    • Gross Profit: 9,877 (+2.4%); COGS: 34.7% (+1.2%); Gross Margin: 67.2% (-0.2%); Operating Profit: 2,980 (+11.6%); Operating Earnings Yield: 20.3% (+8.8%); Net Earnings Yield: 22.0% (39.5%).
    • Product Sales: Gleevec/Glivec: 1,213 (+7.1%); Lucentis: 614 (+5.7%); Gilenya: 653 (+26.1%); Sandostatin: 433 (+8.0%); Afinitor/Votubia: 408 (+21.1%); Tasigna: 391 (+24.1%); Exforge: 365 (+1.7%); Exelon/Exelon Patch: 261 (+3.2%).
    • 2014 Guidance: Group net sales growth: low to mid-single digit (unch); core group operating income: mid to high-single digit (unch).
    | Comment!
  • Oct. 28, 2014, 6:12 AM
    • Novartis (NYSE:NVS): Q3 EPS of $1.33 beats by $0.04.
    • Revenue of $14.7B (+2.5% Y/Y) beats by $360M.
    • Press Release
    | Comment!
  • Oct. 27, 2014, 5:30 PM
  • Oct. 19, 2014, 4:19 PM
    • Novartis (NYSE:NVS) will report Q3 results on October 28 before the open. The webcast begins at 9:00 am ET.
    • Consensus view is EPS of $1.29 on revenues of $14.3B.
    | Comment!
  • Jul. 17, 2014, 7:42 AM
    • Novartis (NYSE:NVS) Q2 pharmaceutical sales by selected product: Gleevec/Glivec: $1,199M (+0.8%); Diovan/Co-Diovan: $743M (-19.9%); Gilenya: $606M (+29.5%); Sandostatin: $417M (+3.2%); Exforge: $370M (-1.9%); Afinitor/Votubia: $384M (+24.7M); Tasigna: $373M (+18.4%); Exelon/Exelon Patch: $246M (-6.5%); Exjade: $244M (+4.3%); Xolair: $197M (+33.1%).
    • Press release
    | Comment!
  • Jul. 17, 2014, 7:37 AM
    • Novartis (NYSE:NVS) Q2 results: Total Revenues: $14,637M (+1.0%); Pharmaceuticals: $8,199M (+1.0%); Alcon: $2,817M (+3.0%); Sandoz: $2,331M (+5.2%); Vaccines: $240M (-41.6%); Consumer Health: $1,050M (+4.6%).
    • COGS: $4,913M (+2.8%); R&D Expense: $2,386 (-2.2%); SG&A Expense: $4,394M (+0.1%); Net Income: $2,585M (+1.5%); EPS: $1.03 (+2.0%); CF Ops: $3,341M (+32.7%); Quick Assets: $7,335M (+39.7%).
    • Gross Profit: $10,278M (+3.6%); COGS: 33.6% (+1.7%); Gross Margin: 70.2% (+2.5%); Operating Profit: $3,095M (+4.2%); Operating Earnings Yield: 21.1% (+3.1%); Net Earnings Yield: 17.7% (+0.4%).
    • 2014 Guidance: Group Net Sales Growth: Low to mid-single digit (unch); Core Group Operating Income: Mid to high-single digit (previously: >sales growth); Pharmaceuticals Growth: in line with 2013 (unch); Alcon Growth: Mid to high-single digit (unch); Sandoz Growth: Mid to high-single digit (unch).
    • Press release
    | Comment!
  • Jul. 17, 2014, 6:22 AM
    • Novartis (NYSE:NVS): Q2 EPS of $1.34 in-line.
    • Revenue of $14.63B (+1.0% Y/Y) misses by $180M.
    • Press Release
    | Comment!
Visit Seeking Alpha's
NVS vs. ETF Alternatives
Company Description
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.